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Abstract
Appropriate dosing of coumarins is difficult to establish, due to significant inter-individual variability in the dose required to
obtain stable anticoagulation. Several genetic and other clinical factors have been associated with the coumarins dose, and
some pharmacogenetic-guided dosing algorithms for warfarin and acenocoumarol have been developed for mixed
populations. We recruited 147 patients with thromboembolic disease who were on stable doses and with an international
normalized ratio (INR) between 2 and 3. We ascertained the influence of clinical and genetic variables on the stable
acenocoumarol dose by multiple linear regression analysis in a derivation cohort (DC; n = 117) and developed an algorithm
for dosing that included clinical factors (age, body mass index and concomitant drugs) and genetic variations of VKORC1,
CYP2C9, CYP4F2 and APOE. For purposes of comparison, a model including only clinical data was created. The clinical factors
explained 22% of the dose variability, which increased to 60.6% when pharmacogenetic information was included
(p,0.001); CYP4F2 and APOE variants explained 4.9% of this variability. The mean absolute error of the predicted
acenocoumarol dose (mg/week) obtained with the pharmacogenetic algorithm was 3.63 vs. 5.08 mg/week with the clinical
algorithm (95% CI: 0.88 to 2.04). In the testing cohort (n = 30), clinical factors explained a mere 7% of the dose variability,
compared to 39% explained by the pharmacogenetic algorithm. Considering a more clinically relevant parameter, the
pharmacogenetic algorithm correctly predicted the real stable dose in 59.8% of the cases (DC) vs. only 37.6% predicted by
the clinical algorithm (95% CI: 10 to 35). Therefore the number of patients needed to genotype to avoid one over- or under-
dosing was estimated to be 5.
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Introduction
Coumarin anticoagulants, including warfarin, acenocoumarol
and phenprocoumon, are highly effective antithrombotic drugs for
the treatment of thromboembolic diseases (such as deep venous
thrombosis and pulmonary embolism), atrial fibrillation and
artificial heart valves [1]. Appropriate dosing of coumarins is
difficult to establish, due to widespread inter-individual variability
in its pharmacokinetics and pharmacodynamic responses and its
narrow therapeutic window. Numerous genetic and non-genetic
factors have been associated with the inter-individual variability in
warfarin and acenocoumarol dosing requirements. Although
warfarin and acenocoumarol are very similar, the recommended
doses are different and they have differences in their pharmaco-
kinetics and pharmacodynamics, as well as in the influence of
genetics and other factors [2]. Thus, the effect of CYP2C9
defective variants is more pronounced for warfarin than for
acenocoumarol and as a consequence the explained variability in
dosing is 10–15% in the case of warfarin and about 5% in the case
of acenocoumarol [3]. Therefore, data on the influence of
pharmacogenetics and other factors on warfarin dose (the most
well-studied to date) to obtain stable anticoagulation are not
applicable to acenocoumarol or phencroumon.
Acenocoumarol, a derivative of coumarin, is commonly used in
Spain and other European countries (France, Ireland, UK,
Netherlands, Austria, Belgium, France, Italy, Portugal, Poland,
Switzerland and Hungary) and numerous countries around the
world (Argentina, Chile, India, Ukraine, Israel, Mexico and
Canada) [4]. Presently, the initial dosing of acenocoumarol is
based mainly on demographic and clinical characteristics, and
later dosing is based on INR results obtained during subsequent
days and weeks. However, there is substantial variability in this
approach, based on the experience and background of the
attending physician. In our Autonomous Community (Madrid)
there are consensus guidelines for oral anticoagulation applicable
to the Regional Health System. Typically, patients start with daily
doses of about 2 mg (1 mg in elderly patients), and thereafter the
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dose is adjusted in accordance with INR test results. Numerous
factors have been associated with the acenocoumarol dose
required to obtain stable anticoagulation, including age, gender,
weight, height, drug interactions and variations in the VKORC1
and CYP2C9 genes [5–6]. Other influential genes, such as CYP4F2
[7–10] and APOE [11–12], have been identified, but their roles are
controversial. Teicher et al. [9] described the minor influence of
CYP4F2 in a genome-wide association study of a prospective
cohort designed to study neurological, cardiovascular, locomotor
and ophthalmological diseases in a population aged 55 years or
older [13]. However, Perez-Andreu et al. [10] have suggested that
CYP4F2 V433M may play an important role in patients with high
dosing requirements. In the case of APOE, only Visser et al. [11]
observed an association between the e4 allele and the required
doses of acenocoumarol.
Given the high rate of adverse effects (including fatal
hemorrhagic events [14–15]) due to incorrectly calculated doses,
it is necessary to develop new strategies for determining the
appropriate weekly dose of acenocoumarol. Several pharmacoge-
netic algorithms for predicting an appropriate warfarin dose have
been proposed [16–25]. Two dosing algorithms for acenocou-
marol have been published. The first [26] was based on 193
outpatients on stable anticoagulation. The authors constructed an
‘‘acenocoumarol-dose genotype score’’ based on the number of
alleles associated with higher acenocoumarol dosage carried by
each subject for each polymorphism, in order to predict those
patients who would require high acenocoumarol doses to achieve
stable anticoagulation. The second was published recently [27],
and included patients on phenprocoumon (n = 229) and aceno-
coumarol (n = 168) treatment. The pharmacogenetic information
included VKORC1 and CYP2C9 genotypes, in addition to
clinical information (weight, height, sex, age and amiodarone).
Their algorithm explained 52.6% of the variance in the
acenocoumarol maintenance dose in the derivation cohort and
49% in the validation cohort. In both cases the population
included patients with a wide range of indications: atrial
fibrillation, cardiac valve replacement, thromboembolic disease,
and other conditions.
After the development of a pharmacogenetic algorithm, the
natural next step is to demonstrate its effectiveness and utility by
mean of a controlled randomized trial. One such trial is being
carried out with warfarin in the USA: NCT01178034 (Clinical-
Trial.gov) including patients with atrial fibrillation. Another trial
has been completed: NCT00511173, including patients with atrial
fibrillation, pulmonary embolism and deep vein thrombosis. In
Europe, a clinical trial is ongoing to test whether the dosing
algorithms for coumarin anticoagulants (including acenocoumarol)
improve the clinical outcomes of patients [28].
The aim of this study was to develop and validate a
pharmacogenetic dosing algorithm for acenocoumarol in a well-
defined cohort of patients with thromboembolic disease. We also
assessed the algorithm’s performance when compared to only
demographic and clinical factors, to evaluate its potential clinical
relevance. This dosing algorithm is currently being tested in a
randomized trial (Eudra CT: 2009-016643-18).
Materials and Methods
Design and setting
This was an observational, prospective, transversal study.
Patients attending the Thromboembolic Disease Unit of the
Internal Medicine Service of La Paz University Hospital (Madrid,
Spain) between 04/2008 and 06/2009 and meeting the selection
criteria were proposed to participate in the study. Ethical
permission for this study was obtained from the Clinical Research
Ethics Committee of La Paz University Hospital of Madrid, Spain
Patients and data collection
The main inclusion criteria were as follows: patients with a
diagnosis of pulmonary embolism and/or deep venous thrombosis
receiving a stable dose of acenocoumarol (weekly dose variation
,20% in the last three months) and an INR within the range of 2
to 3 for at least the three previous months. In order to include
patients with occasional INR out of this therapeutic range of 2–3,
an occasional INR in the range of 1.8 to 3.5 was allowed. These
limits were chosen considering that typically, an acenocoumarol
dose variation below 10% is recommended if INR values are in
this wider range. Exclusion criteria included renal (calculated
creatinine clearance ,30 ml/min), hepatic (Child-Pugh stage C)
or thyroid dysfunction and cancer.
All patient data and blood samples for CYP2C9, VKORC1,
CYP4F2 and APOE genotyping were collected during a visit to the
clinic after written informed consent was obtained. Patient data
collected included: age, gender, race, body weight and height (and
calculated BMI), smoking status, INR results and acenocoumarol
dose administered in the last 3 months, patient’s education level
and concomitant medications. A mini-mental test was also
performed and recorded.
Genotyping
Blood samples were collected in tubes containing EDTA
(ethylenediaminetetraacetic acid) and stored at 220uC before
extraction. DNA was isolated using the QuickGene DNA blood kit
S (FujifilmH, Du¨sseldorf, Germany). KASParH technology (KBios-
ciences, Hoddesdon, UK) was used to detect the CYP2C9*3
(rs1057910), CYP4F2 (rs2108622), VKORC1 (21639
GRA = rs9923231) and APOE (8016 CRT = rs7412 and 7878
TRC = rs429358) variant alleles. TaqmanH technology (Applied
Biosystems, Foster City, USA) was used to detect CYP2C9*2
(rs1799853). The Hardy-Weinberg equilibrium was calculated
with STP-Analyzer 1.2A (Istech, INCH).
Algorithm generation and evaluation of bias and
precision
We randomly chose 80% of the included patients (stratified
according to CYP2C9 genotype nested to VKORC1 A/A vs.
VKORC1 A/G and GG) as the ‘‘derivation cohort’’ (DC) for
developing the dose-prediction model. The remaining 20% of the
patients constituted the ‘‘test cohort’’ (TC), which was used to test
the final model selected.
After preliminary analysis using univariate and various multi-
variate methods and a review of methods used in the literature,
multiple linear regression (MLR) was used to derive the predictive
model. The dependent variable used was the dose needed to
obtain a stable INR (ln-transformed), and as independent variables
we included all the demographic, clinical and genotypic factors
collected (see Table S1).
We performed preliminary MLR using the entire and the
derivation cohorts; the analysis included the ‘‘introducing’’
method, the ‘‘backward’’ step method and the ‘‘forward’’ step
methods available in SPSS. The results are summarized in Table
S2. After this process we choose the variables to be included in the
model, selecting those variables found with p-values consistently
below 0.1 as shown in Table S2. After running the MLR with
these variables, the final model (pharmacogenetic algorithm) was
determined. For comparison, a clinical algorithm was also built,
using only the clinical independent variables used in the previous
Acenocoumarol Pharmacogenetic Algorithm
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model. The p- and b values are provided, reflecting the
significance and the adjusted relative weight, respectively, of each
variable included in the model.
The performance of the pharmacogenetic and clinical models
was evaluated initially in three cohorts: entire, derivation and test.
The calculated uncorrected coefficient of determination (R2) of
each model shows the total variability explained by the model. To
ascertain the contribution of each group of variables to the final
model, we calculated the unadjusted R2, including only the clinical
variables, and consecutively the rest of the variables in the model.
After back transformation of the dose predicted by the models,
we calculated the mean error (ME; mean of the differences
between predicted and observed acenocoumarol doses), mean
absolute error (MAE; absolute difference between predicted and
observed acenocoumarol doses) and the ME and MAE expressed
as a percentage of the observed acenocoumarol dose (%ME and
%MAE). For these parameters, standard deviation and 95%
confidence intervals were also calculated. The ME reflects the bias
in the prediction, and MAE is an estimation of the precision of the
model [29].
All analyses were performed using SPSS 16.0 (Inc., IL, USA).
Clinical relevance
To evaluate the clinical relevance of the models built, we
classified the patients into three dose groups: patients requiring a
low dose (,25th percentile; #11 mg/week), those requiring a high
dose (.75th percentile; $21 mg/week) and those requiring
intermediate doses (25th to 75th percentile). Next, we calculated
the percentage of patients for whom the predicted dose was within
620% of the real stable dose of acenocoumarol.
To evaluate the potential benefit of using the pharmacogenetic
algorithm, we calculated the number needed to genotype (NNG)
as used by the International Warfarin Pharmacogenetics Consor-
tium and defined as the number needed to genotype to avoid
misclassifying one patient (into one of the predefined dose groups)
by the pharmacogenetic model in comparison with the clinical
model [21]. The NNG was computed using the standard ‘‘number
needed to treat’’ method [30]. The NNG is the inverse of the
absolute risk reduction (ARR), calculated as the absolute difference
between the event rates for the pharmacogenetic and clinical
algorithms.
Results
Patient characteristics
A total of 147 Caucasian patients participated in this study
(entire cohort -EC-), 117 in the ‘‘derivation cohort’’ (DC) and 30
in the ‘‘test cohort’’ (TC). The patients’ demographics, genotypes
and concurrent medications are shown in Table 1. No statistical
differences were observed between the derivation and test cohorts.
No patients on amiodarone or enzyme inducers, or carrying APOE
rs7412 fell in the test cohort. Each SNP was in Hardy-Weinberg
equilibrium.
Clinical and pharmacogenetic acenocoumarol dose
algorithms
For both the pharmacogenetic and clinical algorithms, Table 2
shows the clinical, demographic and genotypic independent
variables that were ultimately included in the multiple linear
regression analysis, as well as those variables that were considered
the best at predicting the weekly doses of acenocoumarol needed
to obtain a stable INR. b values and the significance level of each
variable included in the model are also provided in this table.
Table 3 shows the variability explained by clinical factors,
CYP2C9, VKORC1, CYP4F2 and APOE in the pharmacogenetic
algorithm. CYP4F2 and APOE together explain 4.9% of the
variability. The variability explained by the models (R2) was
60.6% for the pharmacogenetic algorithm and 22.0% for the
clinical algorithm (Table 4). This difference is statistically
significant (p,0.001; McNemar’s test of paired proportions).
Bias and precision of pharmacogenetic and clinical
algorithms in the cohorts
Bias (ME and %ME) and Precision (MAE and %MAE) of the
pharmacogenetics model was very similar in the derivation and
test cohorts and therefore in the entire cohort (Table 4). Bias was
very low: 20.66 (SD 5.01), 0.31 (SD 4.99) and 20.46 (SD 5.00) in
the DC, TC and EC respectively. Precision is a more clinically
relevant parameter that was also quite low and very similar
between cohorts; thus the weekly predicted dose deviates from the
actual dose by 3.63 mg (63.50) in the DC, by 3.75 mg (63.24) in
the TC and by 3.65 mg (63.44) in the EC. These differences were
not statistically significant and therefore we can conclude that the
model behaves similarly in the three cohorts.
On the other hand, the performance of the clinical algorithm is
clearly poorer. First, as previously stated, the variability explained
by the clinical variables alone is lower than that obtained by the
pharmacogenetic algorithm: 22.0% versus 60.6% in the DC, 7%
vs. 38.8% in the TC, and 19.0% vs. 56.8% in the EC, with all
differences being statistically significant (see Table 4). Also MAE
(and %MAE) is significantly higher in the clinical algorithm when
compared to the pharmacogenetic algorithm in both derivation
and entire cohorts, although the difference only approaches
statistical significance in the test cohort (p = 0.083 for MAE) due to
its lower size.
From a clinical point of view, a calculation of the percentage of
patients correctly classified within the 620% of the real dose
obtaining a stable INR would be more relevant. The pharmaco-
genetic algorithm correctly predicts the weekly acenocumarol dose
in 57.1% of the EC patients, 59.8% of DC cases, and 46.7% in the
TC cohort. The figures for the clinical algorithm are lower:
34.7%, 37.6% and 23.3%, respectively (see Table 5).
Performance of pharmacogenetic and clinical algorithms
by dose group
As has been shown by other authors [5,6,10,21], most of the
incorrectly dosed patients when using standard initiation doses are
those needing low or high Coumadin doses, and therefore it is
important to analyze the performance of the algorithm in different
dose subgroups. Table 6 shows the differences in precision (in
absolute terms) between the pharmacogenetic and clinical
algorithms in the preformed dose groups. Complete data including
bias and precision in the three cohorts are shown in Table S3. In
the EC, differences in bias and precision parameters between
pharmacogenetic and clinical models are statistically significant in
the low and high dose groups, but do not consistently reach
significance in the intermediate group. In the low dose group, the
dose predicted by the clinical algorithm overestimates the actual
dose by 60.60%; however the dose overestimation of the
pharmacogenetic algorithm is limited to 37.38% (p = 0.005). In
the high dose group, both algorithms underestimate the dose but
to a lesser degree in the pharmacogenetic algorithm: 22.45%,
versus 31.60% in the clinical algorithm (p,0.001). Bias and
precision in the DC is quite similar to that observed in the EC. In
the TC, differences only approach statistical significance in the
high dose group (see Table 6 and Table S3).
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Table 6 also shows a comparison of the percentage of well-
classified patients in the three pre-established dose groups, as
determined by both the pharmacogenetic and clinical models. The
pharmacogenetic algorithm correctly predicts the actual dose for a
higher percentage of patients than the clinical algorithm. For those
patients requiring a low dose, the pharmacogenetic algorithm
Table 1. Characteristics of study cohorts.
Variable Derivation cohort Testing cohort P value
(N=117) (N=30)
Gender [n (%)] 0.29
Male 61 (52.1) 14 (46.7)
Female 56 (47.9) 16 (53.3)
Age, in years [mean (SD)] 67.6 (17) 67.5 (17.7) 0.73
Weight, in kilograms [mean (SD)] 74.3 (15.4) 75.5 (13.5) 0.59
Height, in meters [mean (SD)] 1.63 (0.1) 1.62 (0.1) 0.9
Body mass index (BMI), in kg/m2 [mean (SD)] 27.8 (4.7) 28.6 (4.3) 0.66
Current smoker [n (%)] 12 (10.3) 5 (16.7) 0.96
Mini-mental test [mean (SD)] 27.0 (4.0) 27.0 (3.6) 0.56
Acenocoumarol weekly dose [mean (SD)] 16.7 (7.4) 15.7 (6.0) 0.46
Patients’ education 0.83
No education 14 (12.2) 6 (20.0)
Primary school 55 (47.8) 14 (46.6)
Secondary school 29 (25.2) 6 (20.0)
University degree 17 (14.8) 4 (13.4)
Concurrent medications [n (%)]
Enzyme inducers(1) 5 (4.3) 0 0.25
Enzyme inhibitors(2) 63 (54.7) 16 (53.3) 1.00
Amiodarone 2 (1.7) 0 0.47
Non-steroidal anti-inflammatory drug 17 (14.8) 1 (3.3) 0.12
CYP2C9 genotype [n (%)] (3) 0.62
*1/*1 60 (51.7) 19 (63.3)
*1/*2 37 (31.9) 6 (20)
*1/*3 16 (13.8) 4 (13.3)
*2/*2 or *2/*3 or *3/*3 3 (2.6) 1 (3.3)
VKORC1 genotype [n (%)] 0.34
G/G 49 (41.9) 9 (30)
A/G 49 (41.9) 17 (56.7)
A/A 19 (16.2) 4 (13.3)
CYP4F2 genotype [n (%)](4) 0.24
VV 46 (40.4) 15 (55.6)
VM 54 (47.4) 8 (29.6)
MM 14 (12.3) 4 (14.8)
APOE rs7412 genotype [n (%)] 0.133
C/C 103 (88.0) 23 (76.7)
C/T 12 (10.3) 7 (23.3)
T/T 2 (1.7) 0
APOE rs429358 genotype [n (%)] 0.551
T/T 94 (82.5) 20 (76.9)
T/C 18(15.8) 6 (23.1)
C/C 2 (1.7) 0
(1)CYP inducers that were considered in this analysis included phenytoin, carbamazepine and rifampin.
(2)CYP inhibitors that were considered in this analysis included azoles, proton pump inhibitors and statins.
(3)For CYP2C9 genotype, the usual * designation is used (*2 = rs1799853 and *3 = rs1057910).
(4)VV indicates homozygous V433 carriers; VM, heterozygous V433M carriers; MM, homozygous M433 carriers.
doi:10.1371/journal.pone.0041360.t001
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provides significantly better prediction of the dose than the clinical
algorithm: 41% vs. 13%, (absolute difference: 29%; 95% CI: 11–
46). Similarly, for patients requiring a high dose, the pharmaco-
genetic algorithm performs significantly better than the clinical
algorithm: 44% vs. 18% (absolute difference: 26%; 95% CI: 6–45).
For patients requiring an intermediate dose, the differences are less
and statistical significance is marginal: 77% correct prediction by
the pharmacogenetic algorithm vs. 61% by the clinical algorithm
(absolute difference: 16%; 95% CI: 0–32).
To globally estimate the potential clinical relevance of the
pharmacogenetic algorithm, we calculated the number of patients
needed to genotype (NNG) to avoid over- or under-dosing (i.e.,
misclassifying patients). The global percentage of correctly
classified doses by the pharmacogenetic algorithm in the entire
cohort was 57.1% compared with 36.7% when using only clinical
variables. Therefore the absolute difference is 22% and the NNG
is 4.5 (95% CI: 3–8.8). The figures are similar for the derivation
and test cohort. Table 5 depicts the percentage of patients
misclassified by the pharmacogenetic and clinical algorithms, the
absolute risk reduction (ARR) between both algorithms and the
calculated NNG with their corresponding confidence intervals. In
all cases, the ARR is about 20% and therefore the NNG about 5,
although in the test cohort neither reached statistical significance.
Discussion
Oral anticoagulation with coumarin derivatives is associated
with a high incidence of bleeding complications as well as
therapeutic failures. Every year, 2–5% of patients on anticoagulant
therapy experience serious bleeding, and 0.5–1% of patients have
a fatal bleeding episode [1]. These complications are due to the
narrow therapeutic range of the INR and to the high dose
variability needed to obtain stable anticoagulation, which is
reached after many INR checks and changes to the dose based on
trial and error. Thus, according to Caraco et al., the time needed
to obtain a pharmacodynamic steady state in warfarin-treated
patients is 40.27 days (95% CI, 35.9–44.6 days) [31]. For
acenocoumarol, Gadisseur et al. [32] report that patients are
maintained in the therapeutic range only 30% of the time during
the first 6 weeks of treatment. This lengthy method to obtain an
efficacious and stable INR carries the risk of inefficacy and
increases bleeding episodes in the first month of anticoagulation, as
Table 2. Variables ultimately included in the acenocoumarol pharmacogenetic and clinical dosing algorithms, and values of Beta
reflecting their relative weight in the final model.
Pharmacogenetic algorithm Clinical algorithm
Beta Variable P value Beta Variable P value
Clinical variables
20.294 Age ,0.0001 20.01 Age 0.001
0.240 BMI ,0.0001 0.016 BMI 0.053
0.119 Enzyme inducer status 0.062 0.41 Enzyme inducer status 0.022
20.142 Amiodarone status 0.026 20.45 Amiodarone status 0.13
CYP2C9
20.257 CYP2C9 *1/*3 ,0.0001
20.253 CYP2C9 *2/*2 or *2/*3 or *3/*3 ,0.0001
VKORC1
20.150 VKORC1 A/G 0.039
20.533 VKORC1 A/A ,0.0001
CYP4F2
0.199 CYP4F2 MM 0.002
APOE
0.123 APOE (rs7412)T/T 0.067
Beta: standardized regression coefficient, which reflects the relative weight of each variable included in the model.
doi:10.1371/journal.pone.0041360.t002
Table 3. Unadjusted R2 for each group of variables and
resultant cumulative R2 of the final model.
Pharmacogenetic algorithm
Variable R2(%)
Cumulative
R2(%)
Clinical variables 22.0% 22.0%
Age
BMI
Enzyme inducers status
Amiodarone status
CYP2C9 11.7% 33.7%
CYP2C9 *1/*3
CYP2C9 *2/*2 or *2/*3
or *3/*3
VKORC1 22.0% 55.7%
VKORC1 A/G
VKORC1 A/A
CYP4F2 3.6% 59.3%
CYP4F2 MM
APOE 1.3% 60.6%
APOE (rs7412)T/T
doi:10.1371/journal.pone.0041360.t003
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Table 4. Predictive performance of pharmacogenetic and clinical algorithms.
Pharmacogenetic algorithm Clinical algorithm Difference (95% CI) P value
Derivation cohort
(n=117)
R2{ 60.6%{ 22.0% ,0.001
ME 20.66 (5.01) 21.22 (6.68) 20.55 0.142
(21.29 to 0.18)
MAE 3.63 (3.50) 5.08 (4.48) 1.46 ,0.001
(0.88 to 2.04)
%ME 4.43 (33.59) 8.92 (50.20) 4.49 0.212
(22.60 to 11.58)
%MAE 23.43 (24.38) 34.53 (37.38) 11.09 ,0.001
(5.04 to 17.16)
Testing cohort (n=30)
R2{ 38.8%{ 7.0% ,0.001
ME 0.31 (4.99) 20.13 (5.87) 0.43 0.554
(21.91 to 1.05)
MAE 3.75 (3.24) 4.86 (3.18) 1.11 0.083
(20.16 to 2.37)
%ME 9.96 (34.63) 12.08 (45.76) 2.11 0.761
(211.97 to 16.20)
%MAE 25.76 (24.81) 35.05 (31.21) 9.29 0.138
(23.16 to 21.74)
Entire cohort (n =147)
R2{ 56.8%{ 19.0% ,0.001
ME 20.46 (5.00) 20.99 (6.52) 20.53 0.113
(21.18 to 0.13)
MAE 3.65 (3.44) 5.03 (4.23) 1.38 ,0.001
(0.86 to 1.91)
%ME 5.57 (33.76) 9.57 (49.18) 4.00 0.208
(22.26 to 10.26)
%MAE 23.9 (24.40) 34.64 (36.09) 10.72 ,0.001
(5.34 to 16.11)
ME: mean error (predicted – observed); %ME: mean error expressed as a percentage (%ME = ME/Observed*100); MAE: mean absolute error ( = SQR[(Pred-Obs)2]); %MAE:
mean absolute error expressed as a percentage (%MAE = MAE/Obs*100).
{McNemar’s test of paired proportions.
doi:10.1371/journal.pone.0041360.t004
Table 5. Percentage of global correct classification (Predicted Dose within 620% of Real Dose) by genetic and clinical algorithms
in the derivation, test and entire cohorts.
% correctly classified ARR (95% CI) NNG (95% CI)
Pharmacogenetic Clinical
Derivation cohort (n = 117) 70/117 44/117 22.0% 4.5
59.8% 37.6% (10 to 35)* (2.88 to 10.27)
Testing cohort (n = 30) 14/30 7/30 23.3% 4.3
46,7% 23,3% (0.0 to 47) (22.14 to 1359)
Entire cohort (n = 147) 84/147 51/147 22.0% 4.5
57.1% 34.7% (11 to 34)* (2.98 to 8.81)
*p,0.001
doi:10.1371/journal.pone.0041360.t005
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described by Landefeld et al. [33]. Also, the time within the
therapeutic range strongly correlates with bleeding and the rates of
thromboembolism [34–35].
One potential approach to improving anticoagulant treatment
would be to use a dosing algorithm including demographic and
clinical variables and genetic testing. Some algorithms have been
published for warfarin [16–18,23–25] but only a few for
acenocoumarol [26,27]. Some of these algorithms are in the
process of validation through clinical trials, as previously
mentioned. The population included in this type of study is
usually a broad-spectrum population that mainly includes patients
with atrial fibrillation, prosthetic valves and thromboembolic
disease. On the other hand, the sources of the patients are
registries from hematology and anticoagulation clinics and
therefore are based on retrospective data.
In this article, we describe the development and performance of
a pharmacogenetic algorithm for acenocoumarol dosing in a
prospective cohort of patients with thromboembolic disease. These
patients are typically younger, have fewer concurrent conditions
[36] and have a lower target INR (2 to 3). Clearly, this implies the
theoretical advantage of less variability in the population
characteristics and target INR. A drawback is that application of
our algorithm may be limited mainly to patients with DVT and
PE, and its use in other patients will require prior validation.
However, it must be stressed that in thromboembolic disease it is
crucial to obtain the target INR as soon as possible to avoid a lack
of efficacy as well as excessive coagulation.
Another characteristic of this study is that it is the first
acenocoumarol algorithm including CYP4F2 and APOE in
addition to the well-known VKORC1 and CYP2C9 gene variants,
as well as clinical factors such as age, BMI and interacting drugs.
All together these factors in our model explain 60.6% of the total
variability in the acenocoumarol dose needed to obtain a stable
INR. This percentage is significantly higher compared to the
variability explained when only non-genetic factors are considered.
This explained variability is similar or better than that obtained in
other studies with warfarin [21,23–25] and acenocoumarol
[26,27]. The contribution of CYP4F2 and APOE to the explained
variability in the acenocoumarol dose by our algorithm is 3.6%
and 1.3%, respectively.
The influence of CYP4F2 has been described in several studies
with warfarin and acenocoumarol and has only been included in a
published algorithm for warfarin [23] and in the algorithm
available at WarfarinDosing.org. The contribution of CYP4F2 in
our study is similar to the 4% described by Sagrieya et al. for
warfarin [37] and can be considered relevant.
Apolipoprotein E (APOE) mediates the uptake of vitamin K-rich
lipoproteins in the liver and other tissues. It is a polymorphic
protein defined by three alleles, e2, e3 and e4 (defined by two
SNPs, rs429358 and rs7412), at a single gene locus on
chromosome 19. Visser et al. [11] observed that individuals who
are homozygous or heterozygous for the e4 allele (rs429358)
require significantly lower doses of acenocoumarol to reach the
same level of anticoagulation as patients with the e3/e3 genotype,
and individuals with the e2/e2 or e2/e3 (homozygous or
heterozygous for rs7412, respectively) genotypes require higher
doses of acenocoumarol (however, not a statistically significant
difference). Also Cavallri et al. showed that APOE is associated
with the time to achieve a stable warfarin dose in African-
American patients [38]. To date, APOE has not been considered in
any of the algorithms available. The inclusion of APOE in our
algorithm needs discussion, as it is based on only two patients each
and the statistical significance in the model is slightly above 0.05
(p = 0.067). The inclusion of this variable was based on three facts:
a) all or most of the preliminary regression analyses we performed
included it; b) the weight of the factor in the final model as
reflected by its b value in the model was considered quite high (in
the range of that observed for VKORC1 A/G) and c) it is associated
with the need for higher doses, for which other algorithms perform
more poorly. For example, the IWPG algorithm [21] only
classified 24.8% of the patients needing higher doses of warfarin
correctly. On the other hand, the contribution of APOE (1.3%) to
the total variability explained by our model is low but is still
considered valuable. Several algorithms have included variables
contributing less to the variability and some publications have
considered contributions of this magnitude to be adequate (e.g.,
gender and amiodarone use in the EU-PACT algorithm).
On the other hand, the inclusion of amiodarone in the model is
clearly justified as its influence in the coumarins dose is clearly
established in the literature.
We generated the algorithm using linear regression, which has
the advantages of simplicity and ease of use. This approach has
been previously used by the International Warfarin Pharmacoge-
netics Consortium (IWPC) [21] and by the EU-PACT Study
Table 6. Precision expressed as MAE (SD) of pharmacogenetic and clinical algorithms by dose group in the entire cohort.
Dose Group PhGx algorithm Clinical Algorithm Difference P value*
Low (n=46)
MAE 3.36 (3.13) 4.95 (3.30) 1.59 (3.84) 0.008
0.44 to 2.75
% correctly classified 41% 13% 29 (11 to 46) 0.0049
Median (n=62)
MAE 2.28 (2.04) 2.81 (2.49) 0.52 (2.43) 0.099
20.10 to 1.14
% correctly classified 77% 61% 16 (0 to 32) 0.051
High (n =39)
MAE 6.13 (4.18) 8.62 (4.93) 2.49 (3.08) ,0.001
1.50 to 3.49
% correctly classified 44% 18% 26 (6 to 45) 0.0272
*Between-group comparisons calculated by paired ‘‘t’’ test.
doi:10.1371/journal.pone.0041360.t006
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Group [26]. Also we tested our algorithm in a different cohort that
was randomly obtained from the entire cohort. Obviously, given
that the test cohort is small, its R2 is lower than that of the
derivation cohort (38.8% vs. 60.6%), but bias and precision are
very similar in the test cohort and in the derivation and entire
cohorts (see Table 3). By comparison, using their algorithm, the
IWPC obtained a lower R2 for warfarin in their derivation cohort
than that obtained with our algorithm (47% vs. 60.6%,
respectively) and a higher R2 in their test cohort (43% vs.
38.8%, respectively), as their test cohort was much larger. The
algorithm developed by the EU-PACT Study Group for
acenocoumarol shows a slightly lower R2 value in the derivation
cohort (n = 471): 52.6% for the genotype-guided dosing; in the
validation cohort their figure was 47.3%. As shown in Table 7, we
obtained similar or even better MAEs and percentages of correctly
classified patients according to the actual dose than in the IWPC
and EU-PACT studies. It is worth mentioning that despite the
differences in the type of patients included, the sources of data and
the number of patients included (in addition to the drug itself), the
performance of the genetic algorithms was similar in the three
studies.
When the actual required dose was classified into three groups, the
potential of our algorithm to assign patients into the correct dose
group was good. In those patients needing a standard dose (11–
21 mg/week), the performance of the pharmacogenetic algorithm
was slightly better than the clinical algorithm in the entire and
derivation cohorts (77.0% vs. 61.0% in the EC and 78.9% vs. 61.5%
in the DC) but did not reach statistical significance in the TC cohort
due to the smaller size (70% vs. 60%). However, in the group
requiring lower weekly doses (,11 mg/week, representing 31.3% of
the cohort), the differences in the percentage of correctly classified
patients were clinically relevant and significantly higher using the
pharmacogenetic algorithm (41.0% vs. 13.0% in the EC, 44.1% vs.
14.7% in the DC and 33.3% vs. 8.3% in the TC). A similar result was
found in the high dose group, where the percentage of correctly
classified patients by the pharmacogenetic algorithm was significantly
higher (44.0% vs. 18.0% in the EC, 45.2% vs. 22.6% in the DC and
37.5% vs. 0.0% in the TC). Complete data are detailed in Table S4.
Another important aspect to consider is the over- and
underestimation of the predicted doses in the low and high-dose
groups. In patients needing low doses, both the clinical and
pharmacogenetic algorithms overestimated the dose, but this
overestimation was lower with the pharmacogenetic algorithm (in
the EC it was 3.36 mg/week vs. 4.95 mg/week in the clinical
algorithm). The opposite phenomenon occurred in the patients
needing the highest dose, for whom the better performance of the
pharmacogenetic algorithm over the clinical algorithm was
maintained (6.13 vs. 8.62 mg/week, as in the EC). See the
supplementary material for complete data. This phenomenon was
also observed in the IWPG study [21] but was not evaluated in the
EU-PACT study [26]. In this aspect our algorithm seems to
perform better than the IWPG algorithm when predicting doses
for patients who need higher doses. Across the entire cohort, our
algorithm was able to correctly classify 44% of patients in need of
higher doses, compared to 26.4% in the case of the IWPG
algorithm. These figures were 37.5% and 24.8%, respectively, in
the validation/test cohort. This data suggest that the inclusion of
the CYP4F2 and APOE genotypes, may improve prediction in
patients needing high doses, because these genotypes are
associated with a higher dose of acenocoumarol (and probably
warfarin) to obtain the target INR.
Considering the global benefits of using our acenocoumarol
pharmacogenetic algorithm, the number needed to genotype to
avoid a misclassified patient (NNG) can be calculated to be 5 in
any cohort. This result is at least as clinically relevant as those
obtained by similar studies with warfarin [21]. Therefore if dose
adjustment in clinical practice behaves similar to the clinical
algorithm, this pharmacogenetic algorithm could better predict
the needed acenocoumarol dose and prevent patients from being
over- or undercoagulated.
The main limitation of our study was the limited sample size.
First, we did not have enough patients in the derivation cohort to
include potentially important factors that could influence the
stable dose of acenocoumarol, such as smoking status or other
concurrent medications. Nevertheless, the R2 (60.6%) of our
algorithm (the percentage of dose variability explained by the
model) was higher than that of other acenocoumarol (and
warfarin) dosing algorithms, indicating good performance when
predicting actual doses and indicating more accurate dose
predictions compared to the use of only clinical variables. This
improved prediction was especially true for patients who need low
or high doses and, therefore, have a higher risk of bleeding or re-
thrombosis. Another limitation is the size of the testing cohort,
which was too small to include every type of patient included in
the derivation cohort and to give it enough power for most of the
comparisons. Also this small size would explain the low R2 of the
clinical algorithm. However, the behavior of the pharmacogenetic
algorithm in this cohort is very similar to the performance in the
test or entire cohort in terms of bias and precision measures and in
the percentage of correctly classified patients. The limitation due
to the restricted population (and target INR) has already been
discussed; however, this population restriction also has the
potential advantage of higher specificity, and we can hypothesize
that this could be a reason for the robust performance of our
model despite the low numbers.
Table 7. Comparison of R2 and MAE in our study and two other studies (IWPC and EU-PACT).
IWPC (20) EU-PACT (26) This Study
EC VC DC VC DC/EC VC
(n=4043) (n=1009) (n=375) (n =168) (n =117) (n =30)
R2 47% 43% 52.6% 49.0% 60.6%/56.8% 38.8%
MAE <4.7 <4.7 3.64 3.99 3.63/3.65 3.75
% correctly
classified
<46% <45,5% NA NA 59.8/57.1% 46.7
DC: Derivation cohort; EC: entire cohort; VC: Validation/Testing cohort; MAE: mean absolute error (mg/week). MAE for warfarin dose has been corrected considering a
dose equivalence ratio of 0.57 between both drugs.
doi:10.1371/journal.pone.0041360.t007
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We have not included other genes that have been described to
influence coumarins dosing. Coumarins sensitivity has been also
associated to polymorfirms of c-glutamyl carboxylase (GGCX)
that activates several clotting factors, and to chaperon calumenin
(CALU) which inhibits GGCX, but this later polimorfirms is very
rare in Caucasian and its influence in acenocoumarol dosing seems
to be very low [39].
In conclusion, we have developed the first pharmacogenetic
dosing algorithm for acenocoumarol that includes clinical
variables and information about four genes (VKORC1, CYP2C9,
CYP4F2 and APOE) and that is able to reasonably predict stable
therapeutic doses of acenocoumarol for patients with thrombo-
embolic disease. It would be especially useful in clinical practice
for patients requiring low (,11 mg/week) or high (.21 mg/week)
therapeutic acenocoumarol doses, which represent nearly 60% of
the entire cohort. To test the efficiency and effectiveness of this
pharmacogenetic dosing algorithm for acenocoumarol vs. usual
care, a controlled, randomized, single-blind, multi-center clinical
trial has been designed and is being carried out (Eudra CT:2009-
016643-18). The trial is scheduled to be completed by mid-2012.
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